Refine by
Tumor Growth Articles & Analysis: Older
38 news found
Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of pharmaceutical innovation. Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. ...
An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple immune-suppressive mechanisms in the tumor microenvironment. ...
ByBayer AG
Thus, host responses to cellular stress can influence various stages of cancer development and progression. Tumor cell-derived vascular endothelial growth factors (VEGFs) act on endothelial cells to promote angiogenesis and tumor growth, invasion, and metastasis. At tumor sites, monocytes differentiate into ...
We know IL-2 activates the immune system to attack the tumor, but it can also inhibit this attack and in many cases leads to leakage from blood vessels, which can in turn lead to complications like pulmonary edema, which can be life threatening. Knowing this, we programmed our antibody to activate IL-2 to fight the tumor but at the same time halt IL-2's ability ...
For example, with gene therapy, researchers can target specific genes related to cancer, allowing them to disable the gene responsible for tumor growth. Furthermore, these technological advancements allow doctors to diagnose and treat diseases before they cause significant health issues by editing certain genes causing the disease. ...
By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the ...
Highlights: ES019 phagocytosis activity is corrected with PD-L1 level on tumor cells ES019 leads to better phagocytosis capability of tumor cells by M2-like than M1-like macrophage ES019 activates T cells without induction of phagocytosis of T cells ES019 shows favorable PK in mouse model ES019 demonstrates single agent anti-tumor ...
“Antengene is currently conducting eight clinical studies of XPOVIOâ in mainland China for the treatment of patients with relapsed/refractory hematologic malignancies or solid tumors, and the drug’s safety and efficacy have already been validated in five registrational trials. ...
About PMC-309 PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, an immune checkpoint receptor mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it can play a pivotal role in maintaining the immunosuppressive ...
To date, IO-108 has been well tolerated with demonstrated clinical activity in multiple tumor types, both as a monotherapy and in combination with pembrolizumab, an anti-PD-1 antibody. ...
All patients in Cohorts 5 and 6 had active growth at study entry, as an enrichment strategy to evaluate preliminary efficacy. This group of patients with active growth treated at the therapeutic regimen of three cycles was evaluated for tumor growth rate, tumor control, and visual acuity preservation as the ...
The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. ...
In animal models, sCD80 was well-tolerated and stopped tumor growth by potentially restoring natural anti-tumor immunity (see Lucas A Horn, et al . and Samuel T Haile et al. in collaboration with Dr. Ostrand-Rosenberg). Additionally, strong anti-tumor activity of sCD80 has been reported in multiple tumor types ...
“Specifically, the ability of our technology to target tumor self-antigens and induce a potent T cell response that leads to tumor regression is important as we prepare to file an IND for our HB-300 program in prostate cancer in the third quarter. ...
Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ...
PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today ...
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor ...
The results indicate superior tumor killing and persistence of CAR-NK cells as well as optimal activation of other anti-tumor immune cells. The authors' preclinical research illustrates the benefits of Senti Bio’s calibrated release gene circuit technology to improve CAR-NK cell functions aimed at enhancing solid tumor killing. The poster, ...
Current preclinical studies have shown that small molecule compounds have better ability to inhibit tumor growth and migration than antibodies, and have good biosafety. PD-1/PD-L1 activates human T cells to play an anti-tumor effect by releasing the inhibitory effect of tumor on cellular immunity. Its effectiveness is mainly ...
Intravenous administration of EMI-137 leads to its selective accumulation in c-Met–expressing tumours, which can then be detected optically via fluorescent markers that are attached to the molecular imaging agent. c-Met is a receptor tyrosine kinase, whose over-expression is known to be associated with tumour growth and correlates with a poor clinical prognosis in many ...